A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Antiretroviral Agents, Efavirenz and Raltegravir, at Steady State.
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2012
At a glance
- Drugs Simeprevir (Primary) ; Efavirenz; Raltegravir
- Indications Hepatitis C; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Janssen R&D Ireland
- 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
- 04 Nov 2011 Actual initiation date changed from Dec 2010 to Oct 2010 as reported by ClinicalTrials.gov.
- 23 Jun 2011 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.